Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2446 March 2025

APPLICANT (stamp or sticker acceptable)				PATIENT NHI:	REFERRER Reg No:
Reg No:				First Names:	First Names:
Name:				Surname:	Surname:
Address:				DOB:	Address:
				Address:	
Fax Number:					Fax Number:
Methylph	enid	ate	Hydrochloride Extend	ded Release (Concerta; Ritalin LA)	
practitioner	on th	Diagnosed according to DSM-IV or ICD 10 criteria			
	and			I practitioner or nurse practitioner and confirms that a ast 2 years and has recommended treatment for the p	
		or	which has not been e	rently subsidised formulation of methylphenidate hydroffective due to significant administration and/or difficulancern regarding the risk of diversion or abuse of imm	Ities with adherence
			There is significant oc	moon regarding the nation of diversion of abuse of Illimi	catate release metryspremidate nydroemonde
or	and			uthority criteria for SA2411 methylphenidate hydrochl other methylphenidate hydrochloride presentations ur	
Note: Criterion 2 is to permit short-term funding to cover an out-of-stock on tab extended-release Methylphenidate ER – Teva and tab sustained-release 20 mg Rubifen SR subsidised under SA2411 (https://schedule.pharmac.govt.nz/2025/02/01/SA2411.pdf).					

I confirm the above details are correct and that in signing this form I understand I may be audited.